Combining myostatin inhibition with a weight-loss medication increases the proportion of fat mass lost relative to lean mass compared to weight-loss medication alone.

Study: Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.

When people took a muscle-protecting drug along with a weight-loss pill, they lost the same amount of weight but kept more muscle and lost more fat than those who took only the weight-loss pill.

Study: 1690-P: PG-110, a Novel Bispecific Antibody Targeting ActRII and Myostatin, Enhances Fat-Specific Weight Loss and Improves Bone Health in Combination with GLP-1 Agonist Therapy

When scientists gave mice a weight-loss drug plus a treatment that blocks myostatin (a protein that limits muscle growth), the mice lost more fat but kept their muscle, unlike when they got the weight-loss drug alone. This means the combo helps you lose fat without losing muscle.

Study: 2180-LB: Bimagrumab Augments Metabolic Rate to Improve Incretin-Induced Weight Loss in Obese Mice

When mice were given a muscle-protecting drug along with a weight-loss pill, they lost more fat and kept more muscle than when given the weight-loss pill alone. This suggests the same could happen in people.